Provided by Tiger Trade Technology Pte. Ltd.

Instil Bio, Inc.

7.58
+0.15002.02%
Post-market: 7.580.00000.00%19:30 EDT
Volume:9K
Turnover:69.79K
Market Cap:51.41M
PE:-1.70
High:7.88
Open:7.40
Low:7.40
Close:7.43
52wk High:33.83
52wk Low:5.67
Shares:6.78M
Float Shares:3.62M
Volume Ratio:1.66
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4688
EPS(LYR):-10.7032
ROE:-25.33%
ROA:-10.77%
PB:0.48
PE(LYR):-0.71

Loading ...

Can Iovance (IOVA) Turn Early Amtagvi Data and Manufacturing Tweaks into a Durable Advantage?

Simply Wall St.
·
May 22

Iovance Biotherapeutics to Present at Upcoming Conference

GlobeNewswire
·
May 21

Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

TIPRANKS
·
May 16

Instil Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Instil Bio Q1 Adj. EPS $(0.32) Beats $(0.59) Estimate

Benzinga Earnings
·
May 15

Instil Bio Q1 FY26 net loss narrows to $4.2 million from year-earlier $28.2 million

Reuters
·
May 15

Instil Bio Inc - Q1 2026 Non-Gaap Net Loss per Share $0.32

THOMSON REUTERS
·
May 15

Instil Bio Inc - Cash Position of $74.7 Mln as of March 31, 2026 to Fund Operations Beyond 2027

THOMSON REUTERS
·
May 15

Instil Bio Q1 Basic EPS USD -0.62

THOMSON REUTERS
·
May 15

Press Release: Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 15

Instil Bio Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
May 09

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

GlobeNewswire
·
May 07

TIL Confirms No Deviation in Use of Rs 60 Crore Warrant Proceeds

TIPRANKS
·
May 02

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

GlobeNewswire
·
Apr 27

Instil Bio announces annual shareholder meeting

Reuters
·
Apr 25

Press Release: Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Dow Jones
·
Apr 15

TIL Limited Completes Allotment in Rights Issue, Expands Equity Base

TIPRANKS
·
Apr 10

Instil Bio replaces Deloitte with RSM as independent auditor for fiscal 2026

Reuters
·
Apr 03

Instil Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 01

Instil Bio Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
Mar 30